Logo image of OSRH

OSR HOLDINGS INC (OSRH) Stock Fundamental Analysis

NASDAQ:OSRH - Nasdaq - US68840D1028 - Common Stock - Currency: USD

1.35  -0.04 (-2.88%)

Fundamental Rating

0

Overall OSRH gets a fundamental rating of 0 out of 10. We evaluated OSRH against 555 industry peers in the Biotechnology industry. OSRH has a bad profitability rating. Also its financial health evaluation is rather negative. OSRH has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year OSRH has reported negative net income.
OSRH had a negative operating cash flow in the past year.
In the past 5 years OSRH reported 4 times negative net income.
In the past 5 years OSRH always reported negative operating cash flow.
OSRH Yearly Net Income VS EBIT VS OCF VS FCFOSRH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -1M -2M -3M

1.2 Ratios

The Return On Assets of OSRH (-104.69%) is worse than 77.30% of its industry peers.
Industry RankSector Rank
ROA -104.69%
ROE N/A
ROIC N/A
ROA(3y)-35.61%
ROA(5y)-22.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OSRH Yearly ROA, ROE, ROICOSRH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 50 -50 100 -100 150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OSRH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OSRH Yearly Profit, Operating, Gross MarginsOSRH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, OSRH has less shares outstanding
The debt/assets ratio for OSRH is higher compared to a year ago.
OSRH Yearly Shares OutstandingOSRH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M 8M
OSRH Yearly Total Debt VS Total AssetsOSRH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -11.55, we must say that OSRH is in the distress zone and has some risk of bankruptcy.
OSRH has a Altman-Z score of -11.55. This is in the lower half of the industry: OSRH underperforms 76.58% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -11.55
ROIC/WACCN/A
WACCN/A
OSRH Yearly LT Debt VS Equity VS FCFOSRH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

OSRH has a Current Ratio of 0.07. This is a bad value and indicates that OSRH is not financially healthy enough and could expect problems in meeting its short term obligations.
OSRH has a worse Current ratio (0.07) than 98.20% of its industry peers.
OSRH has a Quick Ratio of 0.07. This is a bad value and indicates that OSRH is not financially healthy enough and could expect problems in meeting its short term obligations.
OSRH's Quick ratio of 0.07 is on the low side compared to the rest of the industry. OSRH is outperformed by 98.02% of its industry peers.
Industry RankSector Rank
Current Ratio 0.07
Quick Ratio 0.07
OSRH Yearly Current Assets VS Current LiabilitesOSRH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M

0

3. Growth

3.1 Past

The earnings per share for OSRH have decreased strongly by -1579.79% in the last year.
EPS 1Y (TTM)-1579.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5140.52%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OSRH. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OSRH Price Earnings VS Forward Price EarningsOSRH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OSRH Per share dataOSRH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for OSRH!.
Industry RankSector Rank
Dividend Yield N/A

OSR HOLDINGS INC

NASDAQ:OSRH (7/3/2025, 10:46:52 AM)

1.35

-0.04 (-2.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.35%
Inst Owner ChangeN/A
Ins Owners0.21%
Ins Owner Change0.34%
Market Cap26.03M
AnalystsN/A
Price TargetN/A
Short Float %1.65%
Short Ratio1.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.7
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS0
BVpS-0.34
TBVpS-0.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -104.69%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.61%
ROA(5y)-22.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.07
Quick Ratio 0.07
Altman-Z -11.55
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1579.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5140.52%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-92.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-167.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-167.22%
OCF growth 3YN/A
OCF growth 5YN/A